MYD88 mutations, particularly the L265P variant, are most commonly associated with lymphoplasmacytic lymphoma and may serve as a useful molecular marker to distinguish this entity from other small B-cell lymphomas and from plasma cell neoplasms [18]. The gene discussed is MYD88; the disease is lymphoplasmacytic lymphoma.